Attorney Docket No.: GPCI-P10-019

REMARKS

Upon entry of this Preliminary Amendment, claims 31-44 constitute the pending claims in the present application. Claims 1-30 are canceled without prejudice. Applicants reserve the right to prosecute claims of identical or similar scope in future applications.

Applicants have added new claims 31-44 to clarify the subject matter claimed. Support for these new claims can be found throughout the specification, including the originally filed claims. For example, page 26, lines 3-10 describe that an antisense nucleic acid can be used to inhibit the translation and/or transcription of a cdc25 DNA and/or RNA. In addition, page 24, lines 19-26, describes the cdc25A genes and equivalent cdc25 genes, which includes all or a portion of the cdc25A genes, or the complement (antisense sequence) thereof. The paragraph immediately prior to this section describes hybridization conditions in detail. Page 25, last paragraph, describes a method of inhibiting mitosis initiation.

CONCLUSION

Applicants believe that the claims are now in condition for allowance and early notification to this effect is earnestly solicited. Any questions arising from this submission may be directed to the undersigned at (617) 951-7000.

If there are any other fees due in connection with the filing of this submission, please charge the fees to our **Deposit Account No. 18-1945.** If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit account.

Date: September 30, 2003

Customer No: 28120 Docketing Specialist Ropes & Gray, LLP One International Place Boston, MA 02110 Phone: 617-951-7000

Fax: 617-951-7050

Respectfully Submitted,

Yu Lu, Ph.D. Patent Agent

Reg. No. 50,306